Proceeds will fund continued development of the Company's ophthalmic treatments, expand the scope and depth of its platform ...
After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...
First patient dosed in first-in-human study evaluating BI 4060107 in people with advanced solid tumors. Clinical development ...
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial ...
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on ...
Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets ...
The hazard ratio (HR) for progression-free survival (PFS) was 0.73 for the combination arm versus nivolumab alone — a 27% ...
OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its third quarter 2026 financial results on ...
Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.
Lynkuet ® (elinzanetant) 60 mg capsules is a neurokinin 1 (NK1) receptor and NK3 receptor antagonist FDA-approved for the ...
About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA ...
Amgen (NASDAQ: AMGN) today announced the appointment of David W. Gibbs to its Board of Directors, effective immediately.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results